PRIVATE & CONFIDENTIAL

Best Viewed on Desktop

For the best experience and to view the full interactive financial models, this prospectus is best viewed on a desktop computer.

Overview Cover
Page 1 of 15
Enlarged View
PRIVATE & CONFIDENTIAL

ALL THE BEAUTY
IN THE WORLD

INVESTMENT PROSPECTUS

PRIVATE & CONFIDENTIAL

NOT FOR DISTRIBUTION BEYOND AUTHORISED RECIPIENTS.

The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all the property or other assets invested.

This document is private and confidential and is for private circulation only to the named recipient. If you are not that person, please return it to the address set out below.

INTRODUCTION

Executive Summary

LEAVE THE WORLD BEHIND TO STAND GUARD OVER THE SILENCE. This solo stage adaptation of Patrick Bringley's memoir explores the ten years he spent working as a guard at the Metropolitan Museum of Art. Following the death of his brother, Bringley left a career at The New Yorker for a role that required little more than standing still and observing. The play inhabits the quiet of the galleries, where the pace of the city is replaced by a routine of patience and endurance. The stage serves as a space where art provides a steady background for the slow process of coming to terms with loss. As an intimate one-man show, the production keeps physical overheads low while delivering a highly focused, emotionally resonant narrative.

The production is directed by Dominic Dromgoole, formerly the Artistic Director of Shakespeare's Globe. Dromgoole applies his experience with classical staging to this intimate narrative, focusing on the relationship between a single individual and the vast history surrounding him. Following its presentation in New York, the show arrives with an established reputation for clear and thoughtful storytelling that translates a personal journey into a collective experience.

Thematically, the piece examines the role of beauty in the face of grief. It considers how we manage loss within a working life and how the act of looking at art can offer a form of quiet resilience. Rather than treating the museum as a static setting, the production uses the visual environment to reflect the internal state of the protagonist. It speaks to an audience looking for a sense of perspective and a grounded reflection on how we find our footing after a life-altering event.

The show is based on a successful New York Times bestseller that has found a wide readership through its honest account of a specific, lived experience. While the book offered a solitary perspective, this adaptation brings that narrative into a shared theatrical environment. It is a work built on the idea that art is a practical resource for navigating difficult times, resulting in a production that is visually composed, emotionally direct, and rooted in reality.

Pieter Bruegel the Elder, "The Harvesters" (1565). The Met.

"Who would have thought that the outstanding art book of the year would have been written not by a curator... but by a museum guard?"
- The Sunday Times
"A beautifully written manual on how to appreciate art, and life. It is a must-read for any art lover."
- Tracy Chevalier, Author of Girl with a Pearl Earring

OFF-BROADWAY ACCLAIM

"Bringley’s script is so quietly perceptive, and Dromgoole’s direction so elegantly restrained, that one might initially underestimate the depth of All the Beauty in the World."
- TheaterScene.net

"The result of their collaboration is a production that combines a lean, shapely script with an authentic solo performance... at once low-key and compelling."
- Off Off Online

"It moves with such calm clarity, so free of theatrical bombast, that its emotional resonance sneaks up on you."
- Stage and Cinema

THE BOOK

"An exquisite portrait of the Met and its treasures that reminds us how to look at the world."
- The Washington Post

Patrick Bringley was twenty-four and building a career at The New Yorker when his older brother died of cancer. In the aftermath, the expectations of a high-achieving life felt increasingly distant and the pace of the city became difficult to manage. Seeking a role that required presence rather than productivity, he left his job to become a security guard at the Metropolitan Museum of Art.

For the next decade, Bringley wore the museum's blue uniform and stood watch over two million square feet of galleries. The book documents his journey through the quiet corners of the institution, moving from the treasures of ancient Egypt to the canvases of the European masters. By stepping out of the typical career path, he found a space where he could process his grief without the pressure to move on or succeed in a conventional sense.

The narrative describes the daily realities of the job and the unique perspective of someone paid to stand still. He shares the stories of his colleagues, a diverse group of people who find their own reasons for working in the silence. He also observes the visitors, noting how people from all walks of life interact with art when they believe no one is watching. Through these interactions, Bringley explores how human beings use creativity to make sense of their own experiences.

All The Beauty In The World is a memoir about the value of slowing down. It details how ten years spent in the company of art allowed Bringley to find his footing again. The book suggests that museums are not just repositories for the past, but practical sanctuaries for the living. It is a straightforward account of how a decade of observation helped a man navigate a personal tragedy and eventually re-engage with the world outside.

Raphael, "Madonna and Child Enthroned with Saints" (ca. 1504). The Met.

CRITICAL RECOGNITION

  • 1. BESTSELLER STATUS: The book is a New York Times bestseller and achieved immediate commercial success upon its release.
  • 2. LITERARY PRIZE: It was awarded the 2023 Marfield Prize, a prestigious national award for non-fiction writing on the arts.
  • 3. CRITICAL RECOGNITION: The Sunday Times named the memoir its Art Book of the Year for its unique perspective on the museum world.
  • 4. ACCOLADES: The work was selected as a Best Book of the Year by The Financial Times, The Guardian, NPR, and the New York Public Library.
  • 5. PEDIGREE: Before joining the museum, Patrick Bringley worked on the editorial staff of The New Yorker magazine.
  • 6. GLOBAL PUBLICATION: The book is published by leading houses including Vintage (Penguin Random House) in the UK and Simon & Schuster in the US.
  • 7. ENGAGEMENT: The memoir maintains a 4.3 rating on Goodreads with over 35,000 reader ratings and thousands of reviews.
  • 8. IMPACT: The text is currently used as a primary source in university humanities seminars, including at Washington University.
  • 9. INSTITUTIONAL AUTHORITY: Bringley now leads official tours and lectures at the Metropolitan Museum of Art as a recognised expert on its collections.
  • 10. MEDIA: The author and his work have been featured in major outlets including The Wall Street Journal, The BBC, and The New York Times.

CASTING

JAMIE MUSCATO
IS PATRICK

Jamie Muscato is currently one of the West End’s most bankable leading men, combining consistent critical acclaim with a highly loyal, ticket buying fanbase. In 2026, his commercial profile reached new heights. Alongside taking over the iconic role of The Emcee in the Olivier Award winning production of Cabaret at the Kit Kat Club, he is set to star as The Phantom in Love Never Dies at the London Palladium this October, anchoring the high-profile celebrations for the fortieth anniversary of The Phantom of the Opera. These major milestones followed significant live concert successes earlier in the year, including two consecutive sold-out solo shows at the Theatre Royal Drury Lane in March 2026, scaling up from his previous sold-out concert residency at Cadogan Hall which was recorded and released as a live album.

Theatre

  • Jamie’s recent stage work includes originating the title role in The Great Gatsby at the London Coliseum, which earned him a 2026 WhatsOnStage Award-winning nomination for Best Actor in a Musical. He also received a 2025 Laurence Olivier Award nomination for Best Actor in a Musical for his performance as Anatole in Natasha, Pierre and The Great Comet of 1812 at The Donmar Warehouse.
  • He is well known for originating the role of JD in the UK premiere of Heathers: The Musical at the Theatre Royal Haymarket and The Other Palace, earning a 2019 WhatsOnStage nomination and establishing the show as a major commercial theatrical brand.
  • His notable leading roles in the West End and across major regional theatres include Christian in Moulin Rouge! at the Piccadilly Theatre, Dexter in One Day at the Royal Lyceum Edinburgh, Guy in Once at the London Palladium, and Enjolras in Les Misérables: The Staged Concert at the Sondheim Theatre.
  • Further stage credits include West Side Story (Leicester Curve), Big Fish (The Other Palace), Lazarus (Kings Cross Theatre), A Subject of Scandal and Concern (Finborough Theatre), Stay Awake Jake (The Vaults), Bend It Like Beckham (Phoenix Theatre), Sweeney Todd (Welsh National Opera), House of Mirrors and Hearts (Arcola Theatre), Dogfight (Southwark Playhouse), The Light Princess (National Theatre), Rock of Ages (Shaftesbury Theatre), Love Story (Duchess Theatre), Les Misérables (25th Anniversary tour), and Spring Awakening (Novello and Lyric Hammersmith).

Film and Television

  • On screen, Jamie recently won the Best Performance in a Drama award at the Kino Festival for the film What We Wished We Could Be. He also starred in the independent feature film The Colour of Spring, winning Best Actor on an international festival circuit that secured 22 awards in total.
  • His television and film credits include prominent roles in Chemistry of Death (Paramount+), The Undeclared War (Channel 4 and Peacock), Danny Boyle’s punk biopic Pistol (FX Network), The Trial of Christine Keeler (BBC), Cilla (ITV), The Nun (Warner Bros), and the feature film adaptation of Les Misérables (Working Title).

Key Awards and Nominations

  • 2026: Nominated for the WhatsOnStage Award for Best Actor in a Musical for The Great Gatsby
  • 2025: Nominated for the Laurence Olivier Award for Best Actor in a Musical for Natasha, Pierre and The Great Comet of 1812
  • 2019: Nominated for the WhatsOnStage Award for Best Actor in a Musical for Heathers
  • Winner: Best Performance in a Drama at the Kino Festival for What We Wished We Could Be
  • Winner: Best Actor at the International Film Festivals Circuit for The Colour of Spring

All casting is subject to final availability

CREATIVES

PATRICK BRINGLEY
AUTHOR

Patrick Bringley is the New York Times bestselling author of All the Beauty in the World, a memoir about his decade working as a guard at the Metropolitan Museum of Art. Named one of the best books of the year by the New York Public Library, the Financial Times, Audible, the Sunday Times (London), and others, the book has resonated globally, with translated editions from Brazil to Ukraine to South Korea, where it became a number one national bestseller.

In the spring of 2025, Patrick starred in an Off-Broadway production of All the Beauty in the World, a solo play he adapted from his book directed by Dominic Dromgoole, formerly the artistic director of the Globe Theatre in London. He has been featured in the New Yorker, the New York Times, NPR, the BBC, CBS, ABC, Fox, and many other outlets, and has lectured at major cultural institutions worldwide, including the National Gallery of Art, the Museum of Fine Arts Boston, the University of Virginia, and venues in Dubai, Dublin, Oxford, and Seoul. He lives with his wife and children in Sunset Park, Brooklyn. All the Beauty in the World is his first book. Crucially, Patrick will be actively involved in the UK marketing and PR campaign for this production, leveraging his international media presence and existing fanbase to drive visibility and ticket sales.

DOMINIC DROMGOOLE
DIRECTOR

Since leaving the Globe in 2016, Dominic Dromgoole has directed one film, Making Noise Quietly, and produced six including The Man In The Hat, Pond Life and Simon Amstell's Benjamin. In the middle of lockdown he directed the Climate Change Concert film Song for Nature in the Coliseum for Sky Arts. At present he is preparing a feature film and a documentary on Shakespeare's First Folio. With his company Classic Spring, he presented the Oscar Wilde Season in the Vaudeville, where he directed the first play A Woman of No Importance. In 2021, he directed El Perro Del Hortelano in Madrid, and in 2022 Nick Dear's version of Frankenstein in Beijing. In 2023 he directed Jordan Harrison's play, Marjorie Prime at the Menier Chocolate Factory.

Dominic was the Artistic Director of Shakespeare's Globe from 2006 to 2016. In that time the Globe built the Sam Wanamaker Playhouse, nurtured an extensive new-writing programme, held the Globe-to-Globe Festival, which hosted companies from 37 different countries, and developed a national and international touring programme which culminated in a two-year tour of Hamlet to every country in the world. Previously Dominic was the Artistic Director of the Oxford Stage Company (now Headlong) 1997-2005, New Writing Director at the Old Vic in 1997, and Artistic Director of the Bush Theatre from 1990-1996. Dominic is also the author of The Full Room: An A-Z of Contemporary Playwriting, Will and Me: How Shakespeare Took Over My Life, Hamlet: Globe to Globe and Astonish Me! First Nights That Changed the World.

THE PRODUCERS

NINA KENEALLY
PRODUCER

Nina Keneally was last represented on Broadway by GOOD VIBRATIONS the musical featuring the music of Brian Wilson and the Beach Boys. Ms. Keneally was both the originator and lead producer of this project. Most recently, in Spring 2025, she produced the acclaimed off-Broadway production of Patrick Bringley’s ALL THE BEAUTY IN THE WORLD.

Read full biography

STACI LEVINE
PRODUCER

Staci Levine is founder and president of Groundswell Theatricals, Inc, a NYC-based producing and general management company. Groundswell has produced on Broadway, Off-Broadway, across North America, London’s West End, Australia, and New Zealand. Current productions include the Arlekin Players Theatre production of The Orchard starring Jessica Hecht and Mikhail Baryshnikov; the podcast Radio Play Revival...

Read full biography

DARREN BELL
PRODUCER

Darren Bell is a three-time winner and six-time nominee at the WhatsOnStage Awards and has built a reputation for producing solo concerts, musicals in concert, and the development of new stage adaptations. His work as a published photographer brought him into the heart of the theatre world, and by 2015 he expanded his creative pursuits to producing. Specializing in showcasing Broadway and West End talent...

Read full biography

SAM QUESTED
EXECUTIVE PRODUCER

Sam has worked in the theatre industry for nearly twelve years, building a wide-ranging career producing and general managing across the West End, national and international tours, and concert productions. His theatre credits include Burlesque the Musical (Savoy Theatre, Manchester and Glasgow). Midnight Cowboy: A New Musical (Southwark Playhouse, Elephant), Bonnie and Clyde (Arts Theatre, Garrick Theatre...

Read full biography

QUBE THEATRICALS
GENERAL MANAGER

QUBE Theatricals is an executive producer and general management company at the forefront of live entertainment, specialising in concerts, musicals in concert, and theatre productions across the West End, national and international tours, and one-night-only events.

Read full biography

FINANCIAL DASHBOARD

PRIVATE & CONFIDENTIAL

Financial Information

This production is capitalised at £263,246 comprising £183,957 of pre-production costs and £64,090 of reserves, which incorporate deposits, VAT, and contingency, and include the cost of the first full running week. Weekly running costs are budgeted at approximately £25,629. The Producers aim to secure a seven-week season at Southwark Playhouse Elephant—a venue with a proven track record for launching major West End transfers, such as *Operation Mincemeat*—and based on current assumptions the projected break-even point for the production is approximately 74.11% capacity, meaning the production is designed to recoup its Production Capitalisation independently.

The Producers currently anticipate an estimated UK Theatre Tax Relief (TTR) claim of approximately £56,507, which is not relied upon for the purposes of meeting weekly running costs and is treated separately from the Production Capitalisation for budgeting and cashflow purposes. All budgets and schedules are illustrations based on the information available to the Producers at the time of this document.

Investments are typically offered in units of £25,000, with fractional units and lower tier amounts available at the Producers' discretion. The budget is currently modelled for the Southwark Playhouse Borough; the budget remains the same for Southwark Playhouse Elephant.

Darren Bell will act as Co-Producer and Co-General Manager of the production via QUBE Theatricals. QUBE Theatricals will receive a £15,000 general management pre-production fee and a £1,000 per week running fee, which are fully accounted for within the respective capitalisation and weekly operating budgets. In addition to management services, Darren Bell is anchoring the production's capitalisation, committing a financial contribution of up to the full capitalisation amount, and in any event, a proportion not less than 50% of the total raise (either independently or in conjunction with a general partner).

Given the limited run, no producer fees will be payable for this engagement. Creative royalties will be payable to the author and rights holder director only. All other creative royalties are waived for this short run engagement.

Key Investor Actions

All figures are for illustrative purposes only and are not a forecast or prediction. All figures are based on current expectations and are subject to change.

INVESTOR STRUCTURE

01 Capital repayment

Prior to recoupment, 100% of the net surplus of the production available for distribution shall be applied to the repayment of Physical Production Capital. Such repayments shall be distributed pari passu to Investors in proportion to their respective subscriptions. The production shall be deemed to have recouped once Physical Production Capital has been repaid in full.

02 Profit participation

Following full repayment of Physical Production Capital, all further distributable receipts shall constitute Net Profits. Net Profits shall be allocated as follows:

  • 60% to Investors, distributed pro rata in accordance with their fractional investment.
  • 40% to the Producers.

03 Key points

  1. Investor funds are held and applied through the Lead Producers' producing entity.
  2. Standard production terms for recoupment, repayment, and ongoing profit participation apply, as detailed in the financial terms below
  3. A full participation agreement will outline distribution procedures, reporting schedules, and investor communications.

Investment Structure

The £263,246 investment or a % thereof will be contributed by Darren Bell and its investor group, forming part of the total production capitalisation.

Investors joining via Darren Bell will participate pro rata in 60% of the Lead Producers’ entitlement, including recoupment and profit participation.

Worked Example

By way of illustration only, if the Lead Producers’ share of Net Profits totals £100,000 in net profit, the investor group (collectively) will receive £60,000, distributed pro-rata to each investor’s contribution.

INVESTOR BENEFITS AND TIERS

Financial Returns

100% repayment of capital prior to recoupment.

Following recoupment, investors participate pro rata in 60% of ongoing net profits.

Core investor entitlement
Opening night

3 pairs of tickets to the official opening performance.

House seats

Priority access to premium house seats.

Crediting

A dedicated biography feature in the official show brochure, subject to tier billing.

Associate Producer

£20,000

3rd line order of investment size.

Designed for investors seeking named production recognition within the available tier structure.

60% terms

Standard Terms

Below £20,000

No title billing.

Participation in the investor group remains subject to the same 60% terms.

60% terms

Participation Note

All investor benefits are subject to availability, the final terms of the participation agreement, and the operational requirements of the production. The financial terms set out above remain subject to the full legal documentation and closing accounts.

BUDGET SUMMARY

PRIVATE & CONFIDENTIAL

PRE PRODUCTION COSTS

Swipe across this table to view all figures.
Development & Advances£5,000
Creative Fees£22,500
Production Staff£30,165
Rehearsals & Salaries£26,367
Tech Charges£14,125
Physical Production£33,250
Admin, Legal, Insurances£24,800
Theatre Costs£3,750
Marketing & PR£29,000
Subtotal Pre-Production Costs£183,957
Contingency£9,198
Total Pre-Production Costs£193,155
Total Development & Pre-Production Costs£198,155
Venue Deposit£18,000
VAT Provision£21,462
1 Week Operating Reserve£25,629
Total Capitalisation (Total Raise)£263,246
Estimated UK TTR (?) [40%]£56,507
Total Recoupable Costs (Dev & Pre-Prod minus TTR)£141,648

WEEKLY OPERATING COSTS

Swipe across this table to view all figures.
Salaries£10,479
Physical£3,950
Theatre Costs£7,600
Marketing & Advertising£1,550
Fixed Fees£0
Admin & Management£1,050
Weekly Royalty Minimums & Fees£1,000
Subtotal Operating Costs£25,629

Budget Summary

Total Capitalisation £263,246
Estimated UK TTR £56,507
Total Recoupable Costs £141,648
Weekly Costs £25,629

RECOUPMENT

PRIVATE & CONFIDENTIAL
Gross Potential £534,068
Average Ticket Price £36.50
Seats Per Performance 236
Performances 62
Total Seats 14,632
Performance Weeks 7.43

Weekly Gross Box Office Potential

£71,894

Total Weekly Operating Costs

£25,629

Total To Recoup

£141,648

ALL THE BEAUTY IN THE WORLD - Recoupment Chart

Swipe across this table to view all scenarios.
Pre Recoupment 100% 90% 85% 80% 75% Break Even
74.11%
Seats to sell 14,63213,16912,43711,70610,97410,844
Gross Box Office Receipts [GBOR] £71,894£64,704£61,110£57,515£53,920£53,281
VAT £11,982£10,784£10,185£9,586£8,987£8,880
CC & Ticket Commissions [3%] £2,157£1,941£1,833£1,725£1,618£1,598
Net Box Office Receipts [NBOR] £57,755£51,979£49,091£46,204£43,316£42,802
Producer Net £57,755£51,979£49,091£46,204£43,316£42,802
Royalties @ 100% of NET £3,793£3,314£3,074£2,834£2,595£2,552
Weekly Operating Surplus £53,962£48,666£46,017£43,369£40,721£40,250
Weekly Operating Costs £25,629£25,629£25,629£25,629£25,629£25,629
Merchandise £6,000£5,400£5,100£4,800£4,500£4,447
Weekly Operating Profit £34,333£28,437£25,489£22,541£19,592£19,068
Total Producer Recoup Value £255,044£211,244£189,344£167,444£145,544£141,648
Total % Recouped 180.05%149.13%133.67%118.21%102.75%100.00%
Post Recoupment Profit £113,396£69,596£47,696£25,796£3,896£0
Weeks To Recoup 4.134.985.566.287.237.43

INTERACTIVE ROI CALCULATOR

PRIVATE & CONFIDENTIAL

Capitalisation: £263,246 | Pool: 60%

£

YOUR ESTIMATED RETURN PROFILE

Your pro-rata equity ownership: 9.497%

Swipe across this table to view all return columns.
Box Office Capacity Total Post-Recoup Profit Your Share of Profit Total Est. Return (Cap + Profit)
100%£113,396£6,461.50£31,461.50
90%£69,596£3,965.70£28,965.70
85%£47,696£2,717.80£27,717.80
80%£25,796£1,469.90£26,469.90
75%£3,896£222.00£25,222.00
74.11% (Break Even)£0£0.00£25,000.00

* Disclaimer: These figures are strictly estimates based on the financial models provided in this prospectus. Theatrical investment is inherently risky and actual returns may vary significantly.

INVESTOR CONDITIONS

Final Accounting and Distributions

Due to the limited run of the production, final recoupment and any investor distributions will be determined following full completion of the production's final closing accounts, including the full and final receipt of the Theatre Tax Relief claim.

Future Transfer and Rollover Position

This investment is made solely into the specific production vehicle capitalising the current limited run at Southwark Playhouse Elephant. In the event of a future commercial transfer, investors are granted a conditional first right of refusal to roll over or reinvest unrecouped capital, returned capital, or earned profits. This right is strictly contingent upon the financial structure, allocation limits, and ultimate approval of the lead producers controlling the subsequent run. The current Producers intend to facilitate the inclusion of existing investors within the new setup wherever possible. However, investors acknowledge that if lead production management changes, or if subsequent producing partners or financial structures restrict outside funding, the opportunity to invest may be modified, reduced, or unavailable.

Tax Note

All figures are for illustrative purposes only and are not a forecast or prediction. All figures are based on current expectations and are subject to change. NOTE: From 1 April 2017 as a result of the removal of Extra Statutory Concession A94 of UK tax law, the producer may be required to deduct tax from profits paid from the theatrical productions to investors that are not a UK registered company. The producer is not qualified to give tax advice and investors should note that the tax implications of making an investment will differ depending upon the investor's individual circumstances. Potential investors are strongly recommended to seek their own independent advice on their tax position prior to applying to invest.

IMPORTANT LEGAL INFORMATION

YOU MUST READ THIS PAGE

PRIVATE & CONFIDENTIAL

DISCLAIMER

Neither the Producer nor any of its affiliates, subsidiaries, officers, employees, agents, advisers, or representatives (together referred to as the "Affiliates") make any representation, warranty, indemnity, or undertaking, express or implied, regarding the truth, accuracy, or completeness of the information contained in this document or any other document or communication (whether written or oral) supplied to any recipient at any time. No responsibility or liability of any kind is accepted by the Producer or any of its Affiliates for any information, statement, opinion, or omission contained herein, or for any loss or damage arising from or in connection with this document or reliance upon it. Nothing in this document, including any illustrative financial projections (the "Projections"), constitutes a profit forecast or a guarantee of future performance. The Projections are provided for illustrative purposes only and merely indicate potential outcomes based on certain assumptions. No representation or assurance is given by the Producer or its Affiliates as to the future performance or success of the matters described herein, and no such inference should be drawn from this document.

KEY RISK FACTORS

1. Inherent Risk: Theatrical production is an inherently risky business. Contributions to the production will involve a higher level of risk than most other financial transactions and there is no probability, but only a possibility, that investors will get back the amount which they invest.

2. Production Costs: Most production costs are incurred prior to opening and will be paid from contributed funds. If the production does not open or fails to proceed, the Producer shall return to contributors, on a pro rata and pari passu basis, any remaining net assets of the production (if any), as determined by the production's certified accountant. Each contributor's share of such return shall be calculated as the proportion of their individual contribution relative to the total capitalisation. Contributors shall have no claim against any other assets of the Producer beyond the production's net assets.

3. Transferability: A contribution to the production is not transferable without the Producer's prior written consent. As there is no established market for such contributions, it may be difficult for contributors to assess their value or fully understand the risks involved. Once an investment is committed and cleared funds are received, it is final and cannot be withdrawn, redeemed, or cancelled at the Investor's discretion. Funds remain at risk for the life of the project, and repayment occurs only under the agreed recoupment terms, except where proven negligence, wilful misconduct, or fraud applies.

4. Private Distribution: This document is for private distribution only and the only person who may enter or offer to enter into any agreement for or with a view to contributing on the basis contained in this document is the person to whom it is addressed and to whom it has been sent by the Producer.

5. Limited Recourse: Investors have no rights against the Producer's assets other than those connected to the production itself. Investments are not protected by any compensation scheme.

6. Corporate Structure: The production will be operated through a dedicated Special Purpose Vehicle (SPV) incorporated as a UK limited company.

7. Fluctuating Income: Income from an investment in the production will vary depending on box office performance.

8. Suitability: The opportunity described in this document may not be suitable for all recipients. Prospective investors are strongly advised to seek independent advice from a financial adviser authorised under the Financial Services and Markets Act 2000 (FSMA) and experienced in theatre and entertainment investments. Where appropriate, specialist tax advice should also be obtained.

9. Cancellation: If for any reason the production fails to open, is cancelled or if having opened fails to attract sufficient audiences, investors may not receive back their contributions, and the Producers shall only return to investors pro rata and pari passu with their respective contributions a proportion of such net assets of the production as are determined to be available.

10. Uninsured Losses: The Producers will not obtain insurance for the production that includes cover in respect of the impact on the production of Covid-19, any variant or any similar virus and as such if, e.g., performances are lost as a result of cast illness or a local or national lockdown or if restrictions are imposed to address Covid-19 (any variant or any similar virus) which impact on rehearsing and/or presenting the production, the production will suffer uninsured losses.

RIGHTS AND SCOPE OF INVESTMENT

UK stage production rights to the production are controlled by Darren Bell under licence from the Author. Investment in the production is limited strictly to the capitalisation of the specific production described in this document and does not confer any ownership interest in, or entitlement to receipts from, any subsequent licensed productions, tours, transfers, revivals, or other exploitations of the work. Investors shall have no financial participation in any licensing income or producer royalties arising from future productions of the production save as expressly set out in any agreed Development Rollover provisions. The Producer and the licensed creatives maintain full artistic and operational autonomy; for the avoidance of doubt, an investment is strictly financial in nature and confers no rights of approval, veto, or consultation regarding i) the selection, hiring, or termination of any creative personnel, production staff, or crew, and ii) the casting of performers or any artistic, stylistic, or creative decisions involving the development or presentation of the work. This document constitutes the entire understanding between the parties; no person is authorised to make representations beyond its contents, and the Producer reserves the right to raise additional capital which may result in the dilution of an Investor's participation. Notwithstanding the foregoing, and where permissible under the terms of any future licence, this document and any related disputes are governed by the laws of England and Wales, and the parties submit to the exclusive jurisdiction of the English courts.

EXEMPTION UNDER SECTION 21 OF FSMA

This communication is made in reliance on Articles 48, 49, 50 and 50A of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended. The Company and Producers are entitled to rely on investor self-certification and are not required to verify eligibility beyond receipt of a valid signed declaration. This document is exempt from the general restriction in Section 21 of FSMA on the communication of invitations or inducements to engage in investment activity, on the grounds that the Recipient is, and will be treated as, a person described below. The investment or investment activity to which this document relates is available only to, and will be engaged in only with, such persons.

(a) High Net Worth Individuals (Article 48 of the FPO)
A person qualifies if at least one of the following applies:
i) Annual income of at least £170,000 in the immediately preceding financial year; or
ii) Net assets throughout the immediately preceding financial year of at least £430,000, excluding the person's primary residence, any loan secured on that residence, rights under a qualifying contract of insurance, and pension or retirement benefits.

(b) Self-Certified Sophisticated Investors (Article 50A of the FPO)
A person qualifies if they have signed the relevant investor statement and at least one of the following applies:
i) They are a member of a network or syndicate of business angels for at least six months; or
ii) They are or have been in the preceding two years working in a professional capacity in the private-equity sector or in the provision of finance for small and medium-sized enterprises; or
iii) They are currently, or have been in the preceding two years, a director of a company with an annual turnover of at least £1.6 million.

This document and its contents are strictly private and confidential. They may not be copied, reproduced, published, or disclosed to any third party without prior written consent. No investment described herein is intended for, nor may it be offered to, any person other than the original recipient. Any person uncertain about the investment described in this document should seek independent advice from an authorised financial adviser under FSMA who specialises in investments of this nature.

READY TO INVEST
OR HAVE QUESTIONS?

Investor Application Form

Please download and complete the investor application form once you have reviewed the investor structure, financial information, investor conditions, and legal information in this deck.

Submitting the form does not create a binding investment commitment. Participation remains subject to investor eligibility, final legal documentation, producer approval, countersignature, and cleared funds.

Email Directly darren.bell@dbce.uk

ATBITW THE PLAY LTD
86-90 PAUL STREET, LONDON, EC2A 4NE